

HEALTHSOUTH CORP  
Form 8-K  
March 01, 2010

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 1, 2010

HealthSouth Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-10315  
(Commission File Number)

63-0860407  
(I.R.S. Employer  
Identification No.)

3660 Grandview Parkway, Suite 200, Birmingham, Alabama 35243  
(Address of Principal Executive Officers, Including Zip Code)

(205) 967-7116  
(Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



ITEM 7.01. Regulation FD Disclosure.

HealthSouth Corporation (“HealthSouth” or the “Company”) will participate in the J.P. Morgan Global High Yield & Leveraged Finance Conference on March 1 - 3, 2010 in Miami, Florida. As part of this conference, representatives of HealthSouth will make a presentation on March 1, 2010 at 5:00 p.m. ET using the slides attached to this Current Report on Form 8-K as Exhibit 99.1.

The Company will also participate in the RBC Capital Markets Healthcare Conference on March 2 – 3, 2010 in New York City, New York. As part of this conference, representatives of HealthSouth will make a presentation using the slides attached to this Current Report on Form 8-K as Exhibit 99.1 and also participate in a post-acute panel discussion on Tuesday, March 2, 2010 at 11:00 a.m. ET.

Both presentations will address, among other things, the Company’s strategy, objectives, and financial performance and discuss industry trends and dynamics. The presentation at the RBC Capital Markets Healthcare Conference will be webcast live and will be available at <http://investor.healthsouth.com> by clicking on an available link.

While the format of certain slides may have changed, the slide presentation attached to this Current Report on Form 8-K as Exhibit 99.1 contains substantially the same information as previously provided in Current Reports on Form 8-K dated February 22, 2010 and January 11, 2010.

The Company uses “same store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same store comparisons are calculated based on hospitals open throughout both the full current periods and throughout the full prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.

The Company also reiterated its guidance for 2010 that was previously provided in a Current Report on Form 8-K dated February 22, 2010 and discussed during the Company’s earnings conference call on February 23, 2010.

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this report is not intended to constitute a determination by the Company that the information is material or that the dissemination of the information is required by Regulation FD.

Note Regarding Presentation of Non-GAAP Financial Measures

The financial data contained in the presentation includes non-GAAP financial measures, including the Company's leverage ratio and Adjusted Consolidated EBITDA. The Company's leverage ratio is defined in its credit agreement as the ratio of consolidated total debt to Adjusted Consolidated EBITDA for the trailing four quarters. The Company continues to believe both its leverage ratio and Adjusted Consolidated EBITDA as defined in its credit agreement are measures of its ability to service its debt and its ability to make capital expenditures.

The Company uses Adjusted Consolidated EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Note 8, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2009 (the “2009 Form 10-K”). These covenants are material terms of the credit

agreement, and the credit agreement represents a substantial portion of the Company's capitalization. Non-compliance with these financial covenants under the credit agreement – its interest coverage ratio and its leverage ratio – could result in the Company's lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders,

---

which would have some cost to the Company, and such relief might not be on terms as favorable to those in the Company's existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted Consolidated EBITDA is critical to the Company's assessment of its liquidity.

In general terms, the definition of Adjusted Consolidated EBITDA, per the credit agreement, allows the Company to add back to or subtract from consolidated net income unusual non-cash or non-recurring items. These items include, but may not be limited to, (1) amounts associated with government, class action, and related settlements, (2) amounts related to discontinued operations and closed locations, (3) charges in respect of professional fees for reconstruction and restatement of financial statements, including fees paid to outside professional firms for matters related to internal controls and legal fees for continued litigation defense and support matters discussed in Note 22, Settlements, and Note 23, Contingencies and Other Commitments, to the consolidated financial statements included in the 2009 Form 10-K, (4) stock-based compensation expense, (5) net investment and other income (including interest income), and (6) fees associated with the Company's divestiture activities.

In accordance with the credit agreement, the Company is allowed to add certain other items to the calculation of Adjusted Consolidated EBITDA, and there may also be certain other deductions required. This includes the interest income associated with income tax recoveries, as discussed in Note 19, Income Taxes, to the consolidated financial statements included in the 2009 Form 10-K. In addition, the Company is allowed to add non-recurring cash gains, such as the cash proceeds from the UBS Settlement (see Note 22, Settlements, to the consolidated financial statements included in the 2009 Form 10-K) to the calculation of Adjusted Consolidated EBITDA. As these adjustments may not be indicative of the Company's ongoing performance, they have been excluded from Adjusted Consolidated EBITDA included in the slide presentation attached as Exhibit 99.1.

However, Adjusted Consolidated EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America ("GAAP"), and the items excluded from Adjusted Consolidated EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted Consolidated EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. The Company reconciles Adjusted Consolidated EBITDA to net income, which reconciliation is set forth in the slide presentation attached as Exhibit 99.1, and to net cash provided by operating activities, which reconciliation is set forth below. Because Adjusted Consolidated EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted Consolidated EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in the 2009 Form 10-K.

The Company also uses adjusted income from continuing operations and the related per share amounts, which amounts are also referred to as "adjusted earnings per share," as analytical indicators to assess its performance. Management believes the presentation of adjusted income from continuing operations and the related per share amounts provides useful information to management and investors about the Company's operating business before taking into account certain items that are non-operational or infrequent in nature. These measures are not defined measures of financial performance under GAAP and should not be considered as alternatives to net income and net income per share available to HealthSouth common shareholders. Because these measures are not measures determined in accordance with GAAP and are susceptible to varying calculations, they may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of operations included in the 2009 Form 10-K for the GAAP measures of net income, income from continuing operations, and basic and diluted earnings per common share. A reconciliation of net income to adjusted income from continuing operations, and the related per share amounts, is included in the slide presentation attached as Exhibit 99.1.

The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company's capacity to reduce debt and pursue development activities. The calculation of adjusted free cash flow is included in the slide presentation attached as Exhibit 99.1. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. Our definition of adjusted free cash flow is limited and does not represent residual cash flows

---

available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2009 Form 10-K for the GAAP measures of cash flows from operating, investing, and financing activities. A reconciliation of net cash provided by operating activities to Adjusted Consolidated EBITDA and adjusted free cash flow is presented below.

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Consolidated EBITDA

|   | For the Year Ended December<br>31, |          |
|---|------------------------------------|----------|
|   | 2009                               | 2008     |
|   | (In Millions)                      |          |
| Net cash provided by operating activities                                       | \$ 406.1                           | \$ 227.2 |
| Provision for doubtful accounts   | (33.1 )                            | (27.0 )  |
| Professional fees—accounting, tax, and legal                                    | 8.8                                | 44.4     |
| Interest expense and amortization of debt discounts and fees                    | 125.8                              | 159.5    |
| Gain (loss) on sale of investments  | 0.8                                | (1.4 )   |
| UBS Settlement proceeds, gross  | (100.0 )                           | -        |
| Equity in net income of nonconsolidated affiliates                              | 4.6                                | 10.6     |
| Net income attributable to noncontrolling interests in<br>continuing operations | (33.4 )                            | (29.8 )  |
| Amortization of debt discounts and fees   | (6.6 )                             | (6.5 )   |
| Distributions from nonconsolidated affiliates                                   | (8.6 )                             | (10.9 )  |
| Current portion of income tax benefit   | (7.3 )                             | (73.8 )  |
| Change in assets and liabilities  | 0.8                                | 53.1     |
| Change in government, class action, and related settlements<br>liability        | 11.2                               | 7.4      |
| Other operating cash used in (provided by) discontinued<br>operations           | 13.5                               | (11.4 )  |
| Other   | 0.4                                | (0.2 )   |
| Adjusted Consolidated EBITDA  | \$ 383.0                           | \$ 341.2 |

## Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

|   | Three<br>Months<br>Ended<br>December<br>31,<br>2009 | Three<br>Months<br>Ended<br>December<br>31,<br>2008 | Year<br>Ended<br>December<br>31,<br>2009 | Year<br>Ended<br>December<br>31,<br>2008 |
|---|---|---|--|--|
| (In Millions)   |   |   |  |  |
| Net cash provided by operating activities                                 | \$ 44.0 (1)   | \$ 77.9 (1)   | \$ 406.1                                 | \$ 227.2                                 |
| Impact of discontinued operations   | 4.1   | (11.9 )   | 13.5                                     | (11.4 )                                  |
| Net cash provided by operating activities of continuing operations        | 48.1  | 66.0  | 419.6                                    | 215.8                                    |
| Capital expenditures for maintenance                                      | (9.6 )  | (17.4 )   | (34.1 )                                  | (42.6 )                                  |
| Net settlements on interest rate swaps                                    | (11.9 )   | (6.8 )  | (42.2 )                                  | (20.7 )                                  |
| Dividends paid on convertible perpetual preferred stock                   | (6.5 )  | (6.5 )  | (26.0 )                                  | (26.0 )                                  |
| Distributions paid to noncontrolling interests of consolidated affiliates | (9.9 )  | (7.1 )  | (32.7 )                                  | (33.4 )                                  |
| Non-recurring items:  |   |   |  |  |
| UBS Settlement proceeds, less fees to derivative plaintiffs' attorneys    | -   | -   | (73.8 )                                  | -  |
| Income tax refunds related to prior periods                               | (4.2 )  | (63.1 )   | (63.7 )                                  | (90.4 )                                  |
| Cash paid for:  |   |   |  |  |
| Professional fees - accounting, tax, and legal                            | 3.8   | 5.3   | 15.3                                     | 18.2                                     |
| Government, class action, and related settlements                         | 0.2   | -   | 11.2                                     | 7.4                                      |
| Adjusted free cash flow   | \$ 10.0   | \$ (29.6 )  | \$ 173.6                                 | \$ 28.3                                  |

- (1) Net cash provided by operating activities for the year ended December 31, 2009 and 2008 was \$406.1 million and \$227.2 million, respectively. Net cash provided by operating activities for the nine months ended September 30, 2009 and 2008 was \$362.1 million and \$149.3 million, respectively, as reported in the Company's Form 10-Q for the quarterly period ended September 30, 2009. The difference is the \$44.0 million and \$77.9 million of net cash provided by operating activities for the three months ended December 31, 2009 and 2008, respectively.

For the three months ended December 31, 2009, net cash used in investing activities was \$8.6 million and resulted primarily from capital expenditures and net settlement payments related to interest rate swaps offset by a decrease in



restricted cash. Net cash used in financing activities during the three months ended December 31, 2009 was \$71.6 million and resulted primarily from net debt payments, debt amendment and issuance costs, distributions paid to noncontrolling interests of consolidated affiliates, and dividends paid on the Company's convertible perpetual preferred stock.

For the three months ended December 31, 2008, net cash used in investing activities was \$28.1 million and resulted primarily from capital expenditures and net settlement payments related to an interest rate swap. Net cash used in financing activities during the three months ended December 31, 2008 was \$42.6 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company's convertible perpetual preferred stock.

For the year ended December 31, 2009, net cash used in investing activities was \$133.0 million and resulted primarily from capital expenditures and net settlement payments related to interest rate swaps. Net cash used in financing activities during the year ended December 31, 2009 was \$224.3 million and resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates, dividends paid on the Company's convertible perpetual preferred stock, and debt amendment and issuance costs.

For the year ended December 31, 2008, net cash used in investing activities was \$40.0 million and resulted primarily from capital expenditures, including expenditures associated with development activities, and net settlement payments related to an interest rate swap offset by proceeds from asset disposals, including our corporate campus. Net cash used in financing activities during the year ended December 31, 2008 was \$176.0 million and

---

resulted primarily from net debt payments made during the period, as well as distributions paid to noncontrolling interests of consolidated affiliates and dividends paid on the Company's perpetual preferred stock, offset by proceeds from the issuance of common stock.

#### Forward-Looking Statements

The information contained in this Current Report on Form 8-K and the slide presentation attached as Exhibit 99.1 includes certain estimates, projections, and other forward-looking information that reflect the Company's current views with respect to future events and financial performance. These estimates, projections, and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.

There can be no assurance that any estimates, projections, or forward-looking information will be realized. All such estimates, projections, and forward-looking information speak only as of the date hereof. The Company undertakes no duty to publicly update or revise the information contained herein or in the slide presentation.

The slide presentation also includes estimates and projections published by the Centers for Medicare and Medicaid Services ("CMS"). HealthSouth is not able to verify those estimates or projections or the detailed calculations thereof by CMS which are not made public. Any changes or errors in those calculations, among other uncertainties such as those referred to below and changes in CMS's own rules and policies, could cause actual results to differ materially from CMS's projections. Furthermore, the Company does not believe that CMS's numbers are consistent with financial reporting results. CMS data and projections should not be used as an indication of financial performance.

You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking information in the slide presentation as it is based on current expectations and general assumptions and is subject to various risks, uncertainties, and other factors, including those set forth in the 2009 Form 10-K and in other documents the Company previously filed with the SEC, many of which are beyond the Company's control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.

#### ITEM 9.01. Financial Statements and Exhibits

##### (d) Exhibits

99.1 Slide presentation of HealthSouth Corporation used in connection with the Company's March 1, 2010 presentation at the J.P. Morgan Global High Yield & Leveraged Finance Conference and the Company's March 2, 2010 presentation at the RBC Capital Markets Healthcare Conference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHSOUTH Corporation

By: /s/ JOHN P. WHITTINGTON  
Name: John P. Whittington  
Title: Executive Vice President,  
General Counsel, and Corporate  
Secretary

Dated: March 1, 2010